RATIONALE: Cabergoline (CAB) is an ergot derivative typically prescribed for the treatment of hyperprolactinemia. It suppresses the release of prolactin through agonist actions on dopamine (DA) D2 receptors; however, it possesses binding affinity for other DA and 5-HT receptors. Side effects that exacerbate valvular heart disease can occur with high doses. OBJECTIVE: The present study examined the acute, subchronic, and chronic dose-response effects of CAB and a derivative dimethylcabergoline (DMC) which acts as an antagonist instead of agonist at 5-HT 2B receptors, on appetitive and consummatory sexual behaviors of male rats. METHODS: CAB (0, 0.03, 0.15, or 0.3 mg/kg/ml) was administered daily to sexually experienced male rats (N = 10/dose) by oral gavage for a total of 68 days. Sexual behavior was tested every 4 days during this period for a total of 16 trials. On the 17th trial, rats were administered their dose of CAB, and 4 h after were overdosed with sodium pentobarbital, perfused intracardially, and their brains processed for Fos immunohistochemistry. DMC (0, 0.03, 0.15, 0.3 mg/kg/ml) was administered daily to sexually experienced male rats (N = 10/dose) by oral gavage for a total of 36 days. Sexual behavior was tested every 4 days for a total of 9 trials. RESULTS: CAB increased anticipatory level changes, intromissions, and ejaculations significantly across all timepoints, with the medium and high doses being most potent. The medium and high doses also increased Fos protein significantly within the medial preoptic area, whereas in the nucleus accumbens shell, the low and medium doses decreased Fos protein but the high dose increased it significantly from control. Similar to CAB, the medium and high doses of DMC increased the number of ejaculations significantly. Rats in all drug dose groups appeared healthy for the duration of the experiments. CONCLUSIONS: Both CAB and DMC facilitate ejaculations, and CAB further facilitates measures of anticipatory sexual motivation and intromissions. These data suggest that both could be used as treatments for sexual arousal disorders and ejaculation/orgasm disorders with little or no untoward side effects at low doses.

Center for Sexual Health and Intervention Czech National Institute of Mental Health 250687 Klecany Czech Republic

Center for Studies in Behavioral Neurobiology Department of Psychology Concordia University Montréal QC H4B 1R7 Canada

Department of Psychiatry University of Minnesota Minneapolis MN 55454 USA

Department of Psychology and Life Sciences Faculty of Humanities Charles University 18200 Prague Czech Republic

Institute for Therapeutics Discovery and Development Department of Medicinal Chemistry University of Minnesota Minneapolis MN 55414 USA

See more in PubMed

Afonso VM, Mueller D, Stewart J, Pfaus JG (2009) Amphetamine pretreatment facilitates appetitive sexual behaviors in the female rat. Psychopharmacology 205:35–43 PubMed DOI

Ahlenius S, Engel J, Larsson K, Svensson L (1982) Effects of pergolide and bromocriptine on male rat sexual behavior. J Neural Transm 54:165–170 PubMed DOI

Allers KA, Dremencov E, Ceci A, Flik G, Ferger B, Cremers TI, Ittrich C, Sommer B (2010) Acute and repeated flibanserin administration in female rats modulates monoamines differentially across brain areas: a microdialysis study. J Sex Med 7:1757–1767 PubMed DOI

Antonini A, Poewe W (2007) Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson’s disease. Lancet Neurol 6:826–829 PubMed DOI

Arnow BA, Millheiser L, Garrett A, Lake Polan M, Glover GH, Hill KR, Lightbody A, Watson C, Banner L, Smart T, Buchanan T, Desmond JE (2009) Women with hypoactive sexual desire disorder compared to normal females: a functional magnetic resonance imaging study. Neuroscience 158:484–502 PubMed DOI

Baum MJ, Everitt BJ (1992) Increased expression of c-fos in the medial preoptic area after mating in male rats: role of afferent inputs from the medial amygdala and midbrain central tegmental field. Neuroscience 50:627–646 PubMed DOI

Berg KA, Harvey JA, Spampinato U, Clarke WP (2008) Physiological and therapeutic relevance of constitutive activity of 5-HT 2A and 5-HT 2C receptors for the treatment of depression. Prog Brain Res 172:287–305 PubMed DOI

Bhattacharyya S, Schapira AH, Mikhailidis DP, Davar J (2009) Drug-induced fibrotic valvular heart disease. Lancet 374:577–585 PubMed DOI

Bitran D, Thompson JT, Hull EM, Sachs BD (1989) Quinelorane (LY163502), a D2 dopamine receptor agonist, facilitates seminal emission, but inhibits penile erection in the rat. Pharmacol Biochem Behav 34:453–458 PubMed DOI

Blackburn JR, Pfaus JG, Phillips AG (1992) Dopamine functions in appetitive and defensive behaviours. Prog Neurobiol 39:247–279 PubMed DOI

Buvat J (2003) Hyperprolactinemia and sexual function in men: a short review. Int J Impot Res 15:373–377 PubMed DOI

Cabilio S (1996) Behavioral scoring program Unpublished software. Concordia University, Montréal

Cantor JM, Binik YM, Pfaus JG (1999) Chronic fluoxetine inhibits sexual behavior in the male rat: reversal with oxytocin. Psychopharmacology 144:355–362 PubMed DOI

Colao A, di Sarno A, Pivonello R, di Somma C, Lombardi G (2002) Dopamine receptor agonists for treating prolactinomas. Expert Opin Investig Drugs 11:787–800 PubMed DOI

Coolen LM, Peters HJ, Veening JG (1998) Anatomical interrelationships of the medial preoptic area and other brain regions activated following male sexual behavior: a combined fos and tract-tracing study. J Comp Neurol 397:421–435 PubMed DOI

Corona G, Rastrelli G, Bianchi N, Sparano C, Sforza A, Vignozzi L, Maggi M (2023) Hyperprolactinemia and male sexual function: focus on erectile dysfunction and sexual desire. Int J Impot Res. https://doi.org/10.1038/s41443-023-00717-1 PubMed DOI

Cosyns B, Droogmans S, Rosenhek R, Lancellotti P (2013) Drug-induced valvular heart disease. Heart 99:7–12 PubMed DOI

Dalló J, Lekka N, Knoll J (1986) The ejaculatory behavior of sexually sluggish male rats treated with (-)deprenyl, apomorphine, bromocriptine and amphetamine. Pol J Pharmacol Pharm 38:251–255 PubMed

Deebel NA, Thai K, Ramasamy R, Terlecki RP (2022) Understanding the dopaminergic pathway relative to men’s sexual dysfunction in patients with Parkinson’s disease: a narrative review with implications for future research. Int J Impot Res. https://doi.org/10.1038/s41443-022-00656-3 PubMed DOI

Devroye C, Cathala A, Di Marco B, Caraci F, Drago F, Piazza PV, Spampinato U (2015) Central serotonin(2B) receptor blockade inhibits cocaine-induced hyperlocomotion independently of changes of subcortical dopamine outflow. Neuropharmacology 97:329–337 PubMed DOI

Doherty PC, Bartke A, Smith MS (1981) Differential effects of bromocriptine treatment on LH release and copulatory behavior in hyperprolactinemic male rats. Horm Behav 15:436–450 PubMed DOI

Dosa PI, Ward T, Walters MA, Kim SW (2013) Synthesis of novel analogs of cabergoline: improving cardiovascular safety by removing 5-HT2B receptor agonism. ACS Med Chem Lett 4:254–258 PubMed DOI PMC

Ferrara N, Bernardini R, Nicoletti F, Drago F, Matera M, Ceravolo A, Scapagnini U (1985) Prolactin influences sexual behavior during aging. J Endocrinol Invest 8(Suppl 2):23–32 PubMed

Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, Sun JH, Link JR, Abbaszade I, Hollis JM, Largent BL, Hartig PR, Hollis GF, Meunier PC, Robichaud AJ, Robertson DW (2000) Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 57:75–81 PubMed

Gebeyehu NA, Gesese MM, Tegegne KD, Kebede YS, Kassie GA, Mengstie MA, Zemene MA, Bantie B, Feleke SF, Dejenie TA, Abebe EC, Anley DT, Dessie AM, Bayih WA, Adela GA (2023) Global prevalence of sexual dysfunction among diabetic patients from 2008 to 2022: systematic review and meta-analysis. Metabol Open 18:100247 PubMed DOI PMC

Gelez H, Clement P, Compagnie S, Gorny D, Laurin M, Allers K, Sommer B, Giuliano F (2013) Brain neuronal activation induced by flibanserin treatment in female rats. Psychopharmacology 230:639–652 PubMed DOI

Giuliano F, Rampin O (2004) Neural control of erection. Physiol Behav 83:189–201 PubMed DOI

González Cautela BV, Quintana GR, Akerman J, Pfaus JG (2021) Acute caffeine reverses the disruptive effects of chronic fluoxetine on the sexual behavior of female and male rats. Psychopharmacology 238:755–764 PubMed DOI

Graham MD, Pfaus JG (2012) Differential effects of dopamine antagonists infused to the medial preoptic area on the sexual behavior of female rats primed with estrogen and progesterone. Pharmacol Biochem Behav 102:532–539 PubMed DOI

Graham MD, Gardner Gregory J, Hussain D, Brake WG, Pfaus JG (2015) Ovarian steroids alter dopamine receptor populations in the medial preoptic area of female rats: implications for sexual motivation, desire, and behaviour. Eur J Neurosci 42:3138–3148 PubMed DOI

Harding SM, McGinnis MY (2005) Microlesions of the ventromedial nucleus of the hypothalamus: effects on sociosexual behaviors in male rats. Behav Neurosci 119:1227–1234 PubMed DOI

Harding SM, McGinnis MY (2004) Androgen receptor blockade in the MPOA or VMN: effects on male sociosexual behaviors. Physiol Behav 81:671–680 PubMed DOI

Hollander AB, Pastuszak AW, Hsieh TC, Johnson WG, Scovell JM, Mai CK, Lipshultz LI (2016) Cabergoline in the treatment of male orgasmic disorder - a retrospective pilot analysis. Sex Med 4:e28–e33 PubMed DOI PMC

Holt RI, Barnett AH, Bailey CJ (2010) Bromocriptine: old drug, new formulation and new indication. Diabetes Obes Metab 12:1048–1057 PubMed DOI

Horvath J, Fross RD, Kleiner-Fisman G, Lerch R, Stalder H, Liaudat S, Raskoff WJ, Flachsbart KD, Rakowski H, Pache JC, Burkhard PR, Lang AE (2004) Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord 19:656–662 PubMed DOI

Hull EM, Dominguez JM (2007) Sexual behavior in male rodents. Horm Behav 52:45–55 PubMed DOI PMC

Ismail N, Laroche C, Girard-Bériault F, Ménard S, Greggain-Mohr JA, Pfaus JG (2010) Conditioned ejaculatory preference in male rats paired with haloperidol-treated females. Physiol Behav 100:116–121 PubMed DOI

Kippin TE, Cain SW, Pfaus JG (2003) Estrous odors and sexually-conditioned neutral odors activate independent neural pathways in the male rat. Neuroscience 117:971–979 PubMed DOI

Kleitz-Nelson HK, Dominguez JM, Cornil CA, Ball GF (2010) Is sexual motivational state linked to dopamine release in the medial preoptic area? Behav Neurosci 124:300–304 PubMed DOI PMC

Konstantinos S, Vikelis M, Rapoport A (2020) Acute care treatment of migraine. J Neuroophthalmol 40:472–484 PubMed DOI

Krüger TH, Haake P, Haverkamp J, Krämer M, Exton MS, Saller B, Leygraf N, Hartmann U, Schedlowski M (2003) Effects of acute prolactin manipulation on sexual drive and function in males. J Endocrinol 179:357–365 PubMed DOI

Krüger THC, Keil L, Jung S, Kahl KG, Wittfoth M, Leeners B, Hartmann U (2018) Lack of increase in sexual drive and function after dopaminergic stimulation in women. J Sex Marital Ther 44:61–72 PubMed DOI

Kvernmo T, Härtter S, Burger E (2006) A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther 28:1065–1078 PubMed DOI

Larner AJ (2008) Transient acute neurologic sequelae of sexual activity: headache and amnesia. J Sex Med 5:284–288 PubMed DOI

Mantegani S, Brambilla E, Varasi M (1999) Ergoline derivatives: receptor affinity and selectivity. Farmaco 54:288–296 PubMed DOI

Mayer J, Sato A, Kiupel M, DeCubellis J, Donnelly T (2011) Extralabel use of cabergoline in the treatment of a pituitary adenoma in a rat. J Am Vet Med Assoc 239:656–660 PubMed DOI

Melis MR, Sanna F, Argiolas A (2022) Dopamine, erectile function and male sexual behavior from the past to the present: a review. Brain Sci 12:826 PubMed DOI PMC

Miyagawa Y, Tsujimura A, Fujita K, Matsuoka Y, Takahashi T, Takao T, Takada S, Matsumiya K, Osaki Y, Takasawa M, Oku N, Hatazawa J, Kaneko S, Okuyama A (2007) Differential brain processing of audiovisual sexual stimuli in men: comparative positron emission tomography study of the initiation and maintenance of penile erection during sexual arousal. Neuroimage 36:830–842 PubMed DOI

Nickel M, Moleda D, Loew T, Rother W, Pedrosa Gil F (2007) Cabergoline treatment in men with psychogenic erectile dysfunction: a randomized, double-blind, placebo-controlled study. Int J Impot Res 19:104–107 PubMed DOI

Parada M, Chamas L, Censi S, Coria-Avila G, Pfaus JG (2010) Clitoral stimulation induces conditioned place preference and Fos activation in the rat. Horm Behav 57:112–118 PubMed DOI

Paredes RG, Lopez ME, Baum MJ (1998) Testosterone augments neuronal Fos responses to estrous odors throughout the vomeronasal projection pathway of gonadectomized male and female rats. Horm Behav 33:48–57 PubMed DOI

Pattij T, Olivier B, Waldinger MD (2005) Animal models of ejaculatory behavior. Curr Pharm Des 11(31):4069–4077

Paxinos G, Watson C (2005) The rat brain in stereotaxic coordinates. Elsevier, New York

Pellis SM, Teitelbaum P, Meyer ME (1990) Labyrinthine and visual involvement in the dorsal immobility response of adult rats. Behav Brain Res 39:197–204 PubMed DOI

Pfaus JG (2009) Pathways of sexual desire. J Sex Med 6:1506–1533 PubMed DOI

Pfaus JG, Heeb MM (1997) Implications of immediate-early gene induction in the brain following sexual stimulation of female and male rodents. Brain Res Bull 44:397–407 PubMed DOI

Pfaus JG, Phillips AG (1991) Role of dopamine in anticipatory and consummatory aspects of sexual behavior in the male rat. Behav Neurosci 105:727–743 PubMed DOI

Pfaus JG, Giuliano F, Gelez H (2007) Bremelanotide: an overview of preclinical CNS effects on female sexual function. J Sex Med 4(Suppl 4):269–279 PubMed DOI

Pfaus JG, Mendelson SD, Phillips AG (1990a) A correlational and factor analysis of anticipatory and consummatory measures of sexual behavior in the male rat. Psychoneuroendocrinology 15:329–340 PubMed DOI

Pfaus JG, Damsma G, Nomikos GG, Wenkstern DG, Blaha CD, Phillips AG, Fibiger HC (1990b) Sexual behavior enhances central dopamine transmission in the male rat. Brain Res 530:345–348 PubMed DOI

Pivonello R, Auriemma RS, Delli Veneri A, Dassie F, Lorusso R, Ragonese M, Liotta M, Sala E, Zarino B, Lai E, Urbani C, Bogazzi F, Mantovani G, Cannavò S, Maffei P, Chiodini P, Colao A (2022) Global psychological assessment with the evaluation of life and sleep quality and sexual and cognitive function in a large number of patients with acromegaly: a cross-sectional study. Eur J Endocrinol 187:823–845 PubMed DOI PMC

Porter MC, Appiah-Kubf LS, Chaudhuri KR (2002) Treatment of Parkinson’s disease and restless legs syndrome with cabergoline, a long-acting dopamine agonist. Int J Clin Pract 56:468–474 PubMed DOI

Pradeep R, Sundarmurthy H, Karan V, Kulkarni P (2019) Prevalence and predictors of femalesexual dysfunction in migraine. Ann Indian Acad Neurol 22:291–294 PubMed DOI PMC

Rubio-Casillas A, Rodríguez-Quintero CM, Rodríguez-Manzo G, Fernández-Guasti A (2015) Unraveling the modulatory actions of serotonin on male rat sexual responses. Neurosci Biobehav Rev 55:234–246 PubMed DOI

Sachs BD, Barfield RJ (1976) Functional analysis of masculine copulatory behavior in the rat. Adv Stud Behav 7:91–154 DOI

Simonsen U, Comerma-Steffensen S, Andersson KE (2016) Modulation of dopaminergic pathways to treat erectile dysfunction. Basic Clin Pharmacol Toxicol 119(Suppl 3):63–74 PubMed DOI

Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, Bays H, Shanahan WR (2010) Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 363:245–256 PubMed DOI

Stolzenberg DS, Numan M (2011) Hypothalamic interaction with the mesolimbic DA system in the control of the maternal and sexual behaviors in rats. Neurosci Biobehav Rev 35:826–847 PubMed DOI

Tobiansky DJ, Roma PG, Hattori T, Will RG, Nutsch VL, Dominguez JM (2013) The medial preoptic area modulates cocaine-induced activity in female rats. Behav Neurosci 127:293–302 PubMed DOI PMC

Vallette S, Serri K, Serri O (2010) Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern? Expert Rev Cardiovasc Ther 8:49–54 PubMed DOI

Wang AT, Mullan RJ, Lane MA, Hazem A, Prasad C, Gathaiya NW, Fernández-Balsells MM, Bagatto A, Coto-Yglesias F, Carey J, Elraiyah TA, Erwin PJ, Gandhi GY, Montori VM, Murad MH (2012) Treatment of hyperprolactinemia: a systematic review and meta-analysis. Syst Rev 1:33 PubMed DOI PMC

Yonezawa A, Yoshizumi M, Ebiko M, Ise SN, Watanabe C, Mizoguchi H, Kimura Y, Sakurada S (2008) Ejaculatory response induced by a 5-HT2 receptor agonist m-CPP in rats: differential roles of 5-HT2 receptor subtypes. Pharmacol Biochem Behav 88:367–373 PubMed DOI

Yonezawa A, Yoshizumi M, Ise SN, Watanabe C, Mizoguchi H, Furukawa K, Tsuru H, Kimura Y, Kawatani M, Sakurada S (2009) Synergistic actions of apomorphine and m-chlorophenylpiperazine on ejaculation, but not penile erection in rats. Biomed Res 30:71–78 PubMed DOI

Yoshizumi M, Yonezawa A, Kimura Y, Watanabe C, Sakurada S, Mizoguchi H (2021) Central mechanisms of apomorphine and m-Chlorophenylpiperazine on synergistic action for ejaculation in rats. J Sex Med 18:231–239 PubMed DOI

Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G (2007) Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med 356:39–46 PubMed DOI